Megakaryopoiesis

Megakaryopoiesis is the complex biological process by which hematopoietic stem cells differentiate into mature, multinucleated megakaryocytes, which ultimately fragment to release platelets into the bloodstream. This process is primarily regulated by the hormone thrombopoietin (TPO) and its interaction with the thrombopoietin receptor (MPL), which is essential for maintaining normal platelet levels (hemostasis). Dysregulation of megakaryopoiesis is a central feature in various hematological disorders; insufficient production leads to thrombocytopenia and bleeding risks, while excessive production is characteristic of myeloproliferative neoplasms like essential thrombocythemia. While megakaryopoiesis itself is a physiological process rather than a single molecular target, it is the primary pathway modulated by therapeutic agents. Thrombopoietin receptor agonists (TPO-RAs), such as romiplostim and eltrombopag, are clinically utilized to stimulate this process to treat low platelet counts in conditions like immune thrombocytopenia and chronic hepatitis C-associated thrombocytopenia.

Other names

ThrombopoiesisMegakaryocyte differentiationPlatelet productionMegakaryocyte maturation

Activation of the Thrombopoietin receptor (MPL) which triggers the JAK/STAT, MAPK, and PI3K/Akt signaling pathways to promote the survival, proliferation, and differentiation of megakaryocyte progenitor cells.